Table 2.
The relationships between CAF, EMT, CSC biomarkers and clinicopathological characteristics
| FAP | P | χ2 | CD10 | P | χ2 | GPR77 | P | χ2 | N-cadherin | P | χ2 | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | + | - | + | - | + | - | + | |||||||||
| Gender | 0.140 | 2.180 | 0.716 | 0.132 | 0.221 | 1.500 | 0.260 | 1.270 | ||||||||
| Male | 73 | 55 | 104 | 24 | 110 | 18 | 77 | 51 | ||||||||
| Female | 30 | 13 | 36 | 7 | 40 | 3 | 30 | 13 | ||||||||
| Age (yr) | 0.793 | 0.069 | 0.228 | 1.451 | 0.417 | 0.660 | 0.327 | 0.959 | ||||||||
| <65 | 82 | 53 | 113 | 22 | 117 | 18 | 87 | 48 | ||||||||
| ≥65 | 21 | 15 | 27 | 9 | 33 | 3 | 20 | 16 | ||||||||
| Tumor location | 0.725 | 1.319 | 0.339 | 3.363 | 0.255 | 4.057 | 0.930 | 0.449 | ||||||||
| Lower third | 51 | 38 | 74 | 15 | 74 | 15 | 55 | 34 | ||||||||
| Middle third | 27 | 14 | 35 | 6 | 39 | 2 | 25 | 16 | ||||||||
| UGEJ | 18 | 13 | 22 | 9 | 28 | 3 | 21 | 10 | ||||||||
| Diffuse | 7 | 3 | 9 | 1 | 9 | 1 | 6 | 4 | ||||||||
| Tumour size (cm) | 0.002 | 10.049 | 0.006 | 7.695 | 0.152 | 2.049 | 0.159 | 1.985 | ||||||||
| <5 | 49 | 16 | 60 | 5 | 60 | 5 | 45 | 20 | ||||||||
| ≥ 5 | 54 | 52 | 80 | 26 | 90 | 16 | 62 | 44 | ||||||||
| ypT Stage | <0.001 | 21.699 | 0.016 | 5.753 | 0.035 | 4.428 | 0.004 | 8.185 | ||||||||
| 0–2 | 36 | 3 | 37 | 2 | 38 | 1 | 32 | 7 | ||||||||
| 3–4 | 67 | 65 | 103 | 29 | 112 | 20 | 75 | 57 | ||||||||
| ypN Stage | 0.001 | 16.972 | 0.034 | 8.689 | 0.118 | 5.872 | 0.032 | 8.834 | ||||||||
| 0 | 49 | 14 | 57 | 6 | 60 | 3 | 46 | 17 | ||||||||
| 1 | 20 | 11 | 26 | 5 | 26 | 5 | 20 | 11 | ||||||||
| 2 | 14 | 15 | 19 | 10 | 23 | 6 | 19 | 10 | ||||||||
| 3 | 20 | 28 | 38 | 10 | 41 | 7 | 46 | 17 | ||||||||
| ypTNM Stage | <0.001 | 24.251 | 0.003 | 11.832 | 0.014 | 8.543 | 0.009 | 9.376 | ||||||||
| I | 30 | 2 | 30 | 2 | 31 | 1 | 26 | 6 | ||||||||
| II | 29 | 14 | 40 | 3 | 41 | 2 | 30 | 13 | ||||||||
| III | 44 | 52 | 70 | 26 | 78 | 18 | 51 | 45 | ||||||||
| Histological types | 0.961 | 0.002 | 0.255 | 1.296 | 0.333 | 0.938 | 0.666 | 0.187 | ||||||||
| Non-low-adhesion adenocarcinoman | 64 | 42 | 84 | 22 | 95 | 11 | 65 | 41 | ||||||||
| Low-adhesion adenocarcinoma | 39 | 26 | 56 | 9 | 55 | 10 | 42 | 23 | ||||||||
| Lauren classification | 0.150 | 2.077 | 0.006 | 7.441 | 0.618 | 0.249 | 0.827 | 0.048 | ||||||||
| Intestinal | 49 | 40 | 66 | 23 | 77 | 12 | 55 | 34 | ||||||||
| Diffuse or Mixed | 54 | 28 | 74 | 8 | 73 | 9 | 52 | 30 | ||||||||
| Degree of differentiation | 0.031 | 4.671 | 0.116 | 2.476 | 0.064 | 3.436 | 0.774 | 0.082 | ||||||||
| Well | 26 | 8 | 31 | 3 | 33 | 1 | 22 | 12 | ||||||||
| Moderate or Poor | 77 | 60 | 109 | 28 | 117 | 20 | 85 | 52 | ||||||||
| Vascular or lymphatic invasion | 0.016 | 5.843 | 0.327 | 0.959 | 0.075 | 3.178 | 0.200 | 1.643 | ||||||||
| No | 86 | 46 | 106 | 26 | 119 | 13 | 86 | 46 | ||||||||
| Yes | 17 | 22 | 34 | 5 | 31 | 8 | 21 | 18 | ||||||||
| Nerve invasion | 0.029 | 4.746 | 0.219 | 1.513 | 0.367 | 0.814 | 0.172 | 1.868 | ||||||||
| No | 87 | 48 | 108 | 27 | 120 | 15 | 88 | 47 | ||||||||
| Yes | 16 | 20 | 32 | 4 | 30 | 6 | 19 | 17 | ||||||||
| Mandard TRG | <0.001 | 43.852 | <0.001 | 15.914 | 0.003 | 9.080 | 0.004 | 8.447 | ||||||||
| 1–2 | 55 | 3 | 57 | 1 | 57 | 1 | 45 | 13 | ||||||||
| 3–5 | 48 | 65 | 83 | 30 | 93 | 20 | 62 | 51 | ||||||||
| Snail1 | P | χ2 | Twist1 | P | χ2 | ALDH1 | P | χ2 | LGR5 | P | χ2 | CD44 | P | χ2 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | + | - | + | - | + | - | + | - | + | |||||||||||
| Gender | 0.092 | 2.838 | 0.624 | 0.241 | 0.086 | 2.941 | 0.301 | 1.068 | 0.760 | 0.094 | ||||||||||
| Male | 87 | 41 | 71 | 57 | 41 | 87 | 51 | 77 | 68 | 60 | ||||||||||
| Female | 35 | 8 | 22 | 21 | 20 | 23 | 21 | 22 | 24 | 19 | ||||||||||
| Age (yr) | 0.337 | 0.923 | 0.874 | 0.025 | 0.951 | 0.004 | 0.484 | 0.490 | 0.539 | 0.377 | ||||||||||
| <65 | 94 | 41 | 73 | 62 | 48 | 87 | 55 | 80 | 71 | 64 | ||||||||||
| ≥65 | 28 | 8 | 20 | 16 | 13 | 23 | 17 | 19 | 21 | 15 | ||||||||||
| Tumor location | 0.906 | 0.559 | 0.657 | 1.612 | 0.258 | 4.028 | 0.226 | 4.349 | 0.876 | 0.690 | ||||||||||
| Lower third | 62 | 27 | 49 | 40 | 37 | 52 | 43 | 46 | 50 | 39 | ||||||||||
| Middle third | 30 | 11 | 21 | 20 | 13 | 28 | 15 | 26 | 20 | 21 | ||||||||||
| UGEJ | 22 | 9 | 19 | 12 | 7 | 24 | 9 | 22 | 17 | 14 | ||||||||||
| Diffuse | 8 | 2 | 4 | 6 | 4 | 6 | 5 | 5 | 5 | 5 | ||||||||||
| Tumour size (cm) | 0.360 | 0.837 | 0.002 | 9.315 | 0.789 | 0.071 | 0.840 | 0.041 | 0.112 | 2.526 | ||||||||||
| <5 | 49 | 16 | 45 | 20 | 24 | 41 | 28 | 37 | 40 | 25 | ||||||||||
| ≥ 5 | 73 | 33 | 48 | 58 | 37 | 69 | 44 | 62 | 52 | 54 | ||||||||||
| ypT Stage | 0.037 | 4.352 | <0.001 | 25.461 | 0.240 | 1.380 | 0.039 | 4.241 | 0.067 | 3.364 | ||||||||||
| 0–2 | 33 | 6 | 35 | 4 | 17 | 22 | 22 | 17 | 26 | 13 | ||||||||||
| 3–4 | 89 | 43 | 58 | 74 | 44 | 88 | 50 | 82 | 66 | 66 | ||||||||||
| ypN Stage | 0.606 | 1.842 | 0.060 | 7.399 | 0.203 | 4.601 | 0.986 | 0.147 | 0.382 | 3.066 | ||||||||||
| 0 | 48 | 15 | 42 | 21 | 27 | 36 | 26 | 37 | 32 | 31 | ||||||||||
| 1 | 23 | 8 | 17 | 14 | 13 | 18 | 14 | 17 | 21 | 10 | ||||||||||
| 2 | 19 | 10 | 14 | 15 | 9 | 20 | 12 | 17 | 14 | 15 | ||||||||||
| 3 | 32 | 16 | 20 | 28 | 12 | 36 | 20 | 28 | 25 | 23 | ||||||||||
| ypTNM Stage | 0.193 | 3.294 | <0.001 | 23.236 | 0.194 | 3.279 | 0.198 | 3.243 | 0.307 | 2.360 | ||||||||||
| I | 27 | 5 | 29 | 3 | 15 | 17 | 18 | 14 | 21 | 11 | ||||||||||
| II | 29 | 14 | 24 | 19 | 17 | 26 | 17 | 26 | 23 | 20 | ||||||||||
| III | 66 | 30 | 40 | 56 | 29 | 67 | 37 | 59 | 48 | 48 | ||||||||||
| Histological types | 0.107 | 2.598 | 0.669 | 0.183 | 0.551 | 0.355 | 0.906 | 0.014 | 0.745 | 0.106 | ||||||||||
| Non-low-adhesion adenocarcinoman | 71 | 35 | 59 | 47 | 36 | 70 | 45 | 61 | 56 | 50 | ||||||||||
| Low-adhesion adenocarcinoma | 51 | 14 | 34 | 31 | 25 | 40 | 27 | 38 | 36 | 29 | ||||||||||
| Lauren classification | 0.011 | 6.442 | 0.460 | 0.546 | 0.576 | 0.312 | 0.443 | 0.588 | 0.035 | 4.466 | ||||||||||
| Intestinal | 56 | 33 | 46 | 43 | 30 | 59 | 35 | 54 | 41 | 48 | ||||||||||
| Diffuse or Mixed | 66 | 16 | 47 | 35 | 31 | 51 | 37 | 45 | 51 | 31 | ||||||||||
| Degree of differentiation | 0.753 | 0.099 | 0.034 | 4.491 | 0.251 | 1.319 | 0.009 | 6.729 | 0.512 | 0.431 | ||||||||||
| Well | 25 | 9 | 24 | 10 | 15 | 19 | 21 | 13 | 20 | 14 | ||||||||||
| Moderate or Poor | 97 | 40 | 69 | 68 | 46 | 91 | 51 | 86 | 72 | 65 | ||||||||||
| Vascular or lymphatic invasion | 0.462 | 0.541 | 0.419 | 0.654 | 0.137 | 2.216 | 0.103 | 2.663 | 0.276 | 1.189 | ||||||||||
| No | 96 | 36 | 74 | 58 | 51 | 81 | 60 | 72 | 74 | 58 | ||||||||||
| Yes | 26 | 13 | 19 | 20 | 10 | 29 | 12 | 27 | 18 | 21 | ||||||||||
| Nerve invasion | 0.777 | 0.081 | 0.827 | 0.048 | 0.650 | 0.206 | 0.660 | 0.194 | 0.539 | 0.377 | ||||||||||
| No | 97 | 38 | 74 | 61 | 47 | 88 | 58 | 77 | 71 | 64 | ||||||||||
| Yes | 25 | 11 | 19 | 17 | 14 | 22 | 14 | 22 | 21 | 15 | ||||||||||
| Mandard TRG | 0.006 | 7.410 | <0.001 | 35.825 | 0.033 | 4.527 | 0.002 | 9.821 | 0.012 | 6.379 | ||||||||||
| 1–2 | 49 | 9 | 50 | 8 | 27 | 31 | 34 | 24 | 39 | 19 | ||||||||||
| 3–5 | 73 | 40 | 43 | 70 | 34 | 79 | 38 | 75 | 53 | 60 | ||||||||||
UGEJ Upper third and gastroesophageal junction